Savita Dandapani, M.D. PARTICIPATING INSTITUTION: City of Hope National Medical Center Duarte, CA City of Hope National Medical Center South Pasadena, CA IRB # 12367 Version Date: 10/24/17 Version: 09 Huntsman Cancer Institute, University of Utah Page 1 of 50 IRB Protocol No. 12367 Version Date: 10/24/2017 Version: 09 C ITY OF HOPE NATIONAL MEDICAL CENTER 1500 E. DUARTE ROAD DUARTE, CA 91010 DEPARTMENT OF MEDICAL ONCOLOGY AND THERAPEUTICS RESEARCH TITLE: RANDOMIZED PHASE II TRIAL OF SIPULEUCEL T IMMUNOTHERAPY PRECEDED BY SENSITIZING RADIATION THERAPY AND SIPULEUCEL-T ALONE IN PATIENTS WITH CASTRATE RESISTANT METASTATIC PROSTATE CANCER CITY OF HOPE PROTOCOL NUMBER: #12367 VERSION: 9 DATE(S) OF AMENDMENT(S)/REVISION(S): Amendment 01 Amendment 02 Amendment 03 Amendment 04 Amendment 05 Amendment 06 Amendment 07 Amendment 08 Amendment 09 May 6, 2013 June 4, 2013 July 18, 2013 August 12, 2013 October 8, 2013 December 11, 2013 January 24, 2014 January 10, 2017 October 24, 2017 DISEASE SITE: PROSTATE CANCER STAGE (if applicable): IV MODALITY: Immunotherapy and Radiation Therapy PHASE/TYPE: II/Randomized PRINCIPAL INVESTIGATOR: Designs protocol, responsible for study conduct and data analysis Cy Stein, M.D . CO-PRINCIPAL INVESTIGATOR: Neeraj Agrawal M.D.